SCHEMBL6763335

SCHEMBL6763335

Cc1c(Cl)ccc(S(=O)(=O)N(CCc2ccccc2)CC(=O)NCC(=O)NCc2ccc(C(N)=NO)cc2)c1Cl

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 3/20 0.58
F10 P00742 2/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
BMP1 P13497 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NCOR2 Q9Y618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763334 1.00 BDKRB1 (0.58) BDKRB1F10TP53LMNAMAPT
SCHEMBL6767064 0.94 BDKRB1 (0.58) BDKRB1F10TP53LMNAMAPT
SCHEMBL7087606 0.91 BDKRB1 (0.55) BDKRB1F10TP53LMNAMAPT
SCHEMBL7087610 0.91 BDKRB1 (0.55) BDKRB1F10TP53LMNAMAPT
SCHEMBL6881504 0.91 BDKRB1 (0.69) BDKRB1F10TP53LMNAMAPT
SCHEMBL6767060 0.89 BDKRB1 (0.61) BDKRB1F10TP53LMNABMP1
SCHEMBL6767059 0.89 BDKRB1 (0.61) BDKRB1F10TP53LMNABMP1
SCHEMBL6881513 0.87 BDKRB1 (0.53) BDKRB1TP53LMNAMAPTHTT
SCHEMBL6762753 0.86 BDKRB1 (0.55) BDKRB1TP53LMNAMAPTHTT
SCHEMBL6982382 0.85 BDKRB1 (0.55) BDKRB1F10TP53LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB BDKRB1 481/4885F10 4430/4885TP53 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.